The human body is able to maintain tight control of blood glucose despite varying glucose consumption, production, and utilization. Two key players involved in maintaining glucose homeostasis are the liver and the hormone insulin which affect each other through various direct and indirect mechanisms…. Insulin Physiology and Metabolism by the …
Read More »New ACP Guidelines for Type 2 Diabetes Treatment
Metformin should be the initial drug for most patients with type 2 diabetes refractory to lifestyle modifications, with a second drug added if needed, according to a new clinical practice guideline from the ACP.…
Read More »ADA: Vascular Status Predicts Hypoglycemia
Type 2 diabetes patients with microvascular or macrovascular complications, or those taking certain monotherapies, are more likely to experience hypoglycemia and require outpatient hospital visits….
Read More »Managing Type 2 Diabetes: Balancing HbA1c and Body Weight
Annie A. Mavian, DO; Stephan Miller, PhD; and Robert R. Henry, MD Abstract: Most patients with type 2 diabetes present with comorbid overweight or obesity. Reaching and maintaining acceptable glycemic control is more difficult in overweight and obese patients, and these conditions are associated with increased risk for cardiovascular and …
Read More »Postprandial Hyperglycemia and Increased Cardiovascular Risk
Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in patients with Type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes …
Read More »Certain Diabetes Therapies May be Associated with Pancreatic Cancer Risks
Metformin appears to reduce the risk for pancreatic cancer in patients with diabetes, whereas insulin therapy appears to increase the risk, according to the results of a large case-control study.
Read More »Metformin Reduces CardioVascular Mortality Risk by 26%
The widely prescribed metformin was alone among oral antidiabetic agents to show a significant effect on cardiovascular (CV) risk in a meta-analysis of 40 select controlled trials. It reduced CV mortality by 26% relative to any other antidiabetic agent or placebo, but there was no effect on all-cause mortality.
Read More »What Is Gpr119 And How Compound Psn821 Might Work
Two weeks ago I wrote about the most promising new diabetes therapies and many of you wanted to know more so this week, Skott Lant, Doctor of Pharmacy Candidate UF College of Pharmacy has prepared a report on What Gpr119 is And How Compound Psn821 Might Work. This is a …
Read More »Endo’s Issue Consensus Statement on Pre-Diabetes
It is good to see that there is more concern for those at risk for diabetes. The treatment of pre-diabetes requires intensive lifestyle modification and the use of metformin and acarbose for controlling glycemia for high-risk patients, declared a consensus statement issued by the American College of Endocrinology task force.
Read More »Metformin as Monotherapy in Overweight or Obese Type 2 Patients
Metformin can help tackle their diabetes while also protecting against diabetes-related organ damage.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.